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Prion diseases are fatal neurodegenerative disorders with unique transmissible properties. The 
infectious and pathological agent is thought to be a misfolded conformer of the prion protein. 
Little is known about the initial events in prion infection because the infecting prion source 
has been immunologically indistinguishable from normal cellular prion protein (PrPC). Here we 
develop a unique cell system in which epitope-tagged PrPC is expressed in a PrP knockdown 
(KD) neuroblastoma cell line. The tagged PrPC, when expressed in our PrP-KD cells, supports 
prion replication with the production of bona fide epitope-tagged infectious misfolded PrP 
(PrPsc). using this epitope-tagged PrPsc, we study the earliest events in cellular prion infection 
and PrP misfolding. We show that prion infection of cells is extremely rapid occurring within 
1 min of prion exposure, and we demonstrate that the plasma membrane is the primary site of 
prion conversion. 
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T
ransmissible spongiform encephalopathies or prion diseases 
are fatal neurodegenerative diseases of humans and animals, 
and are characterized by the accumulation of misfolded prion 
protein (PrPSc) in the brain1. Prion disease is caused by the templated 
misfolding of a normal host cellular prion protein (PrPC) by PrPSc, 
which can be derived either by infection from an exogenous prion 
source (for example, scrapie in sheep, bovine spongiform encepha-
lopathy in cattle and kuru in humans), from the pathological mis-
folding of endogenous PrPC due to mutations in the PrP gene (for 
example, fatal familial insomnia) or due to rare stochastic misfolding 
of normal PrPC protein (for example, sporadic Creutzfeldt-Jakob dis-
ease)2. Neuropathologically, prion diseases show widespread spongi-
osis, neuronal loss and gliosis with strain-specific patterns of neuro-
nal cell tropism. The spread of misfolded prion protein throughout 
the brain from the site of initial prion conversion appears to be a 
process dependent on close cell association, often occurring along 
well-defined synaptic tracts3. There is growing evidence that several 
other proteinopathies that result in neurodegeneration may follow 
a similar prion-like spread of protein misfolding from a localized 
region, making the study of this process relevant to other diseases 
including Alzheimer’s disease and Parkinson’s disease4.
Despite intense efforts, the cell biology of prion conversion and 
trafficking is relatively poorly defined. Cell lines that are susceptible 
to prion infection have been used to model the process in vitro5–7 
but are limited because the infectious agent PrPSc is immunologi-
cally indistinguishable from the PrPC expressed on the recipient 
cell. This means that newly formed PrPSc generated on the recipient 
cell cannot be specifically identified, making the conversion process 
itself difficult to study directly. Previous studies have relied on pro-
longed culture of cell lines that stably propagate prions to clear any 
inocula-derived PrPSc—known to persist in cells for two weeks or 
more8,9—before the cell biology of newly formed PrPSc can be ana-
lysed10. Therefore, fundamental information such as the timescale 
of the infection process or the cellular site in which the initial PrP 
conversion occurs has not been established.
To study the earliest events in cellular prion infection, it is essen-
tial  to  distinguish  the  inocula-derived  PrPSc  species  from  newly 
formed PrPSc generated in the recipient cell. Inserting an epitope 
tag into the sequence of the endogenous PrPC such that the tag can 
be used to differentiate de novo formed PrPSc is an elegant solution 
to this problem; however, the generation of true infectious prions 
containing an epitope tag has yet to be demonstrated in cells. This 
is probably because the sequence sensitivity of the conversion proc-
ess prevents the misfolding of most tagged PrPC molecules11. The 
sequence sensitivity is such that the prion seed (exogenous PrPSc) 
and PrPC substrate (endogenous cellular PrPC) must have homol-
ogous  primary  structures  for  efficient  conversion  to  take  place, 
particularly in certain key regions of the PrP molecule12,13. Hence, 
previous attempts to produce PrP constructs with green fluorescent 
protein reporter inserts or other epitope tags have not generated PrP 
chimerae that are capable of prion conversion14,15.
Here we report on the generation of a unique cell system in 
which  a  novel  epitope-tagged  PrPC  is  expressed  in  a  neuroblas-
toma cell line in which the endogenous PrPC has been silenced by 
RNA interference. We show that this engineered PrPC chimera sup-
ports prion replication and results in the production of a bona fide 
epitope-tagged PrPSc as evidenced by both in vitro assays and mice 
bioassays. Using this cellular system, we have studied the earliest 
events in cellular prion infection and PrP misfolding; we show that 
prion infection of cells is extremely rapid, occurring within 1 min of 
prion exposure, and demonstrate that the plasma membrane is the 
initial site of prion conversion.
Results
Generation of cell lines expressing epitope-tagged PrPSc. To study 
prion infection in cells expressing tagged PrPC constructs without 
any interference from the host wild-type PrPC, we produced PrP 
knockdown  (KD)  cells  derived  from  the  mouse  PK1  prion-
susceptible  neuroblastoma  cell  line16,  using  RNA  interference 
(RNAi) directed at the 3′ untranslated region (3′-UTR) of PrPC 
mRNA. This effectively silences PrP gene expression (Fig. 1a,b) and 
results in the complete inhibition of prion propagation (Fig. 1c). 
This strategy allows the expression of the mouse PrPC open reading 
frame from exogenous constructs lacking the 3′-UTR, and permits 
the expression of a panel of FLAG- and MYC-tagged PrPC chimerae. 
The PrP constructs were designed such that the epitope tags were 
inserted into regions of the murine PrPC sequence that are relatively 
unstructured, and therefore theoretically unlikely to interfere with 
prion  conversion  (Supplementary  Fig.  S1a)12,17.  Wild-type  PK1 
cells, PrP-KD cells and cells expressing tagged PrPC constructs were 
exposed to Rocky Mountain Laboratory (RML) mouse prions, and 
their ability to support prion propagation was assayed using the 
Scrapie Cell Assay16. PrP constructs 22CysFLAG and 30GlyFLAG 
were found to reconstitute prion propagation very efficiently and 
contained high levels of PrPSc. However, it became apparent during 
the  course  of  our  study  that  these  amino  (N)-terminal  FLAG 
tags  were  readily  cleaved  during  cellular  processing  such  that 
a proportion of the tagged PrPSc in the cells was not detected by 
the anti-FLAG antibodies, making them unsuitable for this study. 
Cells  expressing  PrPC  with  epitope  tags  placed  centrally  within 
the PrP sequence (for example, PrP-124AlaMYC, Supplementary   
Fig. S1a) did not support prion propagation (Fig. 1c). However, 
cells expressing PrP-224AlaMYC with the epitope tag inserted near 
the carboxy (C)-terminus were found to propagate prions robustly 
and reproducibly (Fig. 1c). Immunofluorescence and immunoblot 
analyses  demonstrate  that  the  expression  levels  and  the  cellular 
distribution of PrP-224AlaMYC were similar to that of wild-type 
PrPC in PK1 cells (Fig. 1a,b). Immunoblotting of proteinase K (PK)-
digested  cell  lysates  from  RML  prion-infected  PrP-224AlaMYC 
cells  demonstrates  that  they  contain  protease-resistant  PrP,  a 
characteristic feature of PrPSc18 (Supplementary Fig. S1b).
PrP-224AlaMYC cells propagate infectious tagged prions in vivo. 
To confirm that our infected PrP-224AlaMYC cells were generat-
ing bona fide prions, the infectious nature of the 224-AlaMYC-
PrPSc  was  analysed  in  tg20  mice,  a  transgenic  mouse  line  that 
overexpresses PrP often used in prion bioassays19. The mice were 
inoculated intracerebrally with extracts from RML prion-infected 
PrP-224AlaMYC-expressing cells. PK1 and PrP-KD cells infected 
in parallel with these cultures were used as positive and negative 
controls, respectively. Importantly, inoculation of tg20 mice with 
extracts from RML prion-infected PrP-KD cells (that do not propa-
gate prions) did not result in prion disease in the mice (Fig. 1d,e and 
Table 1). Inoculation of tg20 mice with RML prion-infected PrP-
224AlaMYC cell extracts resulted in early clinical signs of scrapie, 
whereas extracts from control PrP-224AlaMYC cultures that were 
not previously exposed to RML prions did not (Table 1). Biochemi-
cal analysis of the brains of the scrapie-affected mice showed that 
they contained PK-resistant PrPSc (Fig. 1d). Histological analyses 
revealed classical prion neuropathology with PrP deposition, neu-
ronal loss, spongiosis and gliosis (Fig. 1e). Control animals killed in 
parallel with the scrapie-affected mice did not contain PrPSc or show 
any pathological features (Fig. 1d,e). These experiments demon-
strate that our PrP-KD cells expressing PrP-224AlaMYC propagate 
true infectious tagged prions following RML prion exposure, and 
cause disease indistinguishable from that caused by RML prions 
propagated in wild-type PK1 cells.
Characterization of MYC-tagged PrPSc cellular distribution. To 
perform a detailed analysis of prion infection in cultured cells, it is 
necessary to distinguish newly synthesized PrPSc from the host cellu-
lar PrPC. Three established methods achieve this by utilizing the   ARTICLE     
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biochemical differences between native PrPC and misfolded PrPSc:   
These are PK digestion, guanidinium hydrochloride (GdnHCl) dena-
turation and formic acid extraction20,21. We compared each method   
in detail by immunostaining our PrP-224AlaMYC-expressing cells 
with  anti-MYC  antibodies.  Both  PK  and  formic  acid  treatment 
revealed a population of PK and formic acid-resistant MYC-tagged 
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Figure 1 | Generation of prion-susceptible cell lines expressing epitope-tagged PrPC and PrPSc. (a) Western blots developed with anti-PrP and anti-
mYC antibodies showing levels of PrPC in PK1, PrP-KD, PrP-124GlymYC and PrP-224AlamYC cell extracts. Actin is used as a loading control. Quantitative 
densitometry of similar blots that showed PrP expression was reduced by 90–95% in our PrP-KD cells. (b) merged confocal images of PK1, PrP-KD and 
PrP-224AlamYC cells stained with anti-PrP antibodies (green) and counterstained with 6-diamidino-2-phenylindole (blue) are shown; scale bar, 20 µm. 
(c) scrapie Cell Assay (sCA) data showing the relative prion susceptibility of cell lines expressing PrP-mYC constructs compared with PrP-KD cells. Cells 
exposed to RmL prions (red bars) or control cells (blue bars) were processed for the sCA. PrP molecules with the mYC tag inserted near the C-terminus 
at Ala224 support prion propagation; 124GlymYC cells, uninfected PrP-224AlamYC cells and infected PrP-KD cells do not contain PrPsc. The mean ± s.e.m. 
of six independent experiments are shown. (d) Tg20 mice inoculated intracerebrally with extracts of prion-infected PrP-224AlamYC cells develop prion 
disease. Western blots developed with anti-PrP antibodies showing that tg20 mice inoculated with extracts of prion-infected PK1 and PrP-224AlamYC 
cells generate PK-resistant PrP (PrPsc) with a triplet band pattern similar to that of RmL prions. (e) Histological analysis of tg20 mice brains inoculated 
with extracts of RmL prion-infected PK1 cells (iPK1) and PrP-224AlamYC cells (iPrP-224AlamYC) revealed classical prion neuropathology with PrPsc 
deposition (ICsm35 immunostaining), neuronal loss and spongiosis (hematoxylin and eosin, H&E staining) and gliosis (GFAP immunostaining). Brains 
from animals inoculated with extracts of RmL prion-infected PrP-KD cells (iPrP-KD) or control uninfected PrP-224AlamYC cells (PrP-224AlamYC) did not 
contain PrPsc or show other diagnostic features. scale bar is 80 µm on the H&E stained sections and 160 µm for all other panels.ARTICLE
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PrPSc in prion-infected cells (Fig. 2a,b), with a strong signal at the 
plasma membrane and in the perinuclear compartment (PNC), con-
sistent with previous observations of the sub-cellular distribution of 
PrPSc (refs 20,22,23). In contrast, only very low levels of background 
immunostaining were detected in uninfected cells, indicating that 
PrPC  had  been  effectively  removed  by  these  treatments.  GdnHCl 
denaturation was less effective at removing PrPC staining (Fig. 2a,b). 
Similar results were obtained using ScPK1 cells that express wild-type 
PrPSc (ref. 20) (Supplementary Fig. S2a,b), indicating that our MYC-
tagged PrPSc displays a physiologically relevant cellular localization.
The distribution of the formic acid-resistant MYC-tagged PrPSc 
in PrP-224AlaMYC cells was analysed in detail by dual staining of 
formic acid-treated cells with anti-MYC and anti-PrP antibodies; 
importantly, anti-MYC and anti-PrP antibody staining colocalized 
(Fig. 2c). Further, dual staining experiments using anti-MYC anti-
bodies and antibodies directed against various intracellular mark-
ers show partial colocalization of these compartments with formic 
acid-resistant MYC-tagged PrPSc (Supplementary Fig. S3), consist-
ent with previous reports7,20,22,24 and validating the use of formic acid 
treatment to reveal PrPSc in cultured cells.
MYC-tagged PrPSc is rapidly formed following prion exposure. 
Our  novel  cell  system  expressing  MYC-tagged  PrPSc  combined 
with effective PrPC removal by formic acid or PK treatment allows 
de novo synthesized PrPSc to be clearly distinguished from the host 
RML prion inocula. This makes a detailed temporal and spatial 
study of the early stages of cellular prion infection feasible. Previous 
work in the field suggests that a 72-h exposure to prion-infected 
material is necessary to fully infect susceptible cells16. Therefore, we 
first infected PrP-224AlaMYC cells with RML prions for 3 days, and 
either fixed immediately or passaged in fresh media before fixation, 
formic acid extraction and anti-MYC staining. Maximum numbers 
of RML prion-infected MYC-tagged PrPSc cells were seen 6 days 
post infection (DPI; Fig. 3a) and stable prion propagation in ~20% 
of the cells was observed up to 14 DPI (Fig. 3a). PrP-KD cells treated 
in the same way showed no anti-MYC immunostaining up to 6 DPI 
(Fig. 3a), indicating that the observed staining was dependent on 
PrP-224AlaMYC expression. Interestingly, a significant proportion 
of the PrP-224AlaMYC cells already contained MYC-tagged PrPSc 
after 3 days of RML prion exposure (Fig. 3a). This prompted us to   
examine the first 72 h of prion exposure in more detail. Figure 3b  
shows  the  proportion  of  infected  cells  at  different  time  points   
of  RML  prion  exposure  and  reveals  that  PrP-224AlaMYC  cells   
produce  PrPSc  rapidly,  with  MYC-tagged  PrPSc-positive  prion-
infected cells clearly detectable after 2 h of RML prion exposure. 
These observations suggest that cellular prion infection is faster 
than previously thought. Therefore, we examined the first few min-
utes of prion exposure in more detail. PrP-224AlaMYC cells were 
exposed to RML prions for very short periods before rapid wash-
ing and fixation. A significant proportion of the cells showed clearly 
detectable levels of formic acid-resistant MYC-tagged PrPSc after as 
little as 1 min of exposure to RML prions (Fig. 3c), the shortest time 
period technically possible to reproduce accurately within the limi-
tations of our system. PK digestion of similar cells confirmed that 
protease-resistant MYC-tagged PrPSc was generated after very short 
periods of prion exposure (Fig. 3d).
Further  experiments  (Supplementary  Fig.  S4)  confirmed  that 
prion infection is rapid in our system. Washing the cells to remove 
inocula  before  culturing  the  cells  in  the  fresh  media  (without   
inocula), demonstrated that short periods of RML prion exposure   
are sufficient to generate stable PrPSc propagation in our cells. Quan-
tifying the anti-MYC label incorporated into PrP-224AlaMYC cells 
following  RML  prion  exposure  showed  that  MYC-tagged  PrPSc 
builds  up  rapidly,  reaching  maximium  levels  by  2 h,  which  are 
maintained for at least 24 h. We also found that the proportion of 
prion-susceptible PrP-224AlaMYC cells was not increased if higher 
concentrations of inocula were applied.
Prion conversion occurs at the cell surface within 1 min. The steep 
rise in the number of prion-infected cells observed in the first 2 min 
following RML prion exposure indicates that this is the period when 
most cells first begin to synthesize PrPSc (Fig. 3c). This allowed us to 
study the cellular site of this initial prion conversion. Examination of 
cells that were fixed after 1 min of prion exposure revealed that the 
MYC-tagged PrPSc signal is only present at the plasma membrane. 
Orthogonal projections of serial confocal sections clearly showed 
that PrPSc is present only at the cell surface (Fig. 4a—1 min, white 
arrows—the z stack series is shown in Supplementary Fig. S5a).   
This  cellular  distribution  is  strikingly  different  from  the  more   
typical plasma membrane and intracellular localization observed   
in cells that have been exposed to RML prions for longer durations 
(Fig. 4a—180 min, arrows—the z stack series is shown in Supple-
mentary Fig. S5b). Categorizing the cells into three phenotypes of 
different PrPSc distributions (plasma membrane, plasma membrane/
diffuse  intracellular  and  plasma  membrane/PNC),  and  examin-
ing  each  phenotype  at  different  durations  following  RML  prion 
exposure revealed a rapid transition from the plasma membrane 
distribution seen at the earliest time point to the typical plasma 
membrane/PNC distribution observed later (Fig. 4b). Indeed, cells 
showing exclusively plasma membrane MYC-tagged PrPSc staining 
disappeared after 2 min of exposure to RML prions, consistent with 
rapid PrPSc formation, endocytosis and trafficking.
Table 1 | In vivo bioassay of the infectious properties of the novel tagged-PrP molecules generated in PrP-224AlaMYC cells.
Inocula SCA (PrPSc positive  
cells)
Incubation time  
(days)  
Analysis
Pathological Biochemical
PrP-224AlaMYC cells
   + RmL 321 67 ± 1.03* 4/4 2/2
  Control 24 — 0/2 0/4
PK1 cells
   + RmL 1628 66 ± 1.38 5/5 2/2
PK1-10Si8 PrP-KD cells
   + RmL 15 — 0/2 0/4
RmL, Rocky mountain Laboratory; sCA: scrapie cell assay.
sCA (the mean from six replicates is shown).
standard histopathological analysis as shown in Figure 1e was performed on the indicated number of animals from each group—prion disease was confirmed by H&E, GFAP and PrPsc staining.
Biochemical analysis as shown in Figure 1d was performed on the indicated number of animals from each group—prion disease was confirmed by the detection of PK resistant PrP in brain homogenates. 
*mean±s.d., n4.ARTICLE     
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Figure 2 | Characterization of de novo MYC-tagged PrPSc distribution in RML prion-infected cells. (a) Comparison of the methods used to visualize PrPsc 
in RmL prion-infected cells. uninfected PrP-224AlamYC cells (top panels) or chronically RmL prion-infected PrP-224AlamYC cells (passage five following 
prion exposure—bottom panels) were fixed and treated with 98% formic acid, proteinase K (PK) or guanidinium hydrochloride (GdnHCl) before staining 
with anti-mYC antibodies (green) and counterstaining with 6-diamidino-2-phenylindole (DAPI, blue). merged confocal images are shown; scale bar, 
20 µm. A proportion of the RmL prion-infected cells contain formic acid and PK-resistant PrP (PrPsc) with a characteristic plasma membrane/perinuclear 
compartment distribution (arrow). (b) Quantification of randomly chosen cell fields from uninfected PrP-224AlamYC cells (blue bars) or chronically RmL 
prion-infected PrP-224AlamYC cells (red bars). Approximately 20% of the cells in cultures exposed to RmL prions contain formic acid/PK-resistant PrP 
(PrPsc). The background staining observed in the uninfected PrP-224AlamYC cells after formic acid and PK treatment is mostly attributable to clumped 
cells in which access to the PrPC is restricted. The mean ± s.e.m. from four independent experiments are shown. (c) Chronically RmL prion-infected PrP-
224AlamYC cells were fixed and treated with 98% formic acid before staining with anti-mYC antibodies (green) and anti-PrP antibodies (red); the cells 
were counterstained with DAPI (blue). single channels and merged confocal images are shown as indicated; scale bar, 20 µm.ARTICLE
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To confirm this result, we directly compared the formation and 
trafficking of MYC-tagged PrPSc to the endocytosis of Texas red-
labelled transferrin. Transferrin endocytosis and trafficking occurs 
rapidly, reaching a steady-state distribution at the PNC between 8 
and 16 min25 (Fig. 4c). In the same cells, PrPSc attained a steady-
state distribution in nearly all cells by 4 min of exposure to prions   
(Fig.  4b,c).  Therefore,  prion  protein  conversion  and  endocytosis 
proceeds at rates that are similar to that of transferrin trafficking.
To determine whether PrP prion conversion can occur on the 
plasma membrane, we incubated pre-cooled PrP-224AlaMYC cells 
with RML prions at 4 °C. This temperature shift effectively abolished 
endocytosis in mammalian cells26. Significantly, PrPSc accumulated 
only on the cell surface under these conditions (Fig. 5a,b, 4 °C). 
Orthogonal projections of confocal sections taken through these 
infected cells revealed the plasma membrane distribution of MYC-
tagged PrPSc (Fig. 5a—the z stack series is shown in Supplementary 
Fig. S6) and clearly demonstrated that endocytosis is not necessary 
to produce misfolded PrP.
To test this hypothesis, we used a range of pharmacological and 
genetic manipulations designed to inhibit the endocytic pathways 
that were previously implicated in prion metabolism—dynamin- 
and clathrin-dependent endocytosis and macropinocytosis. Dyna-
sore was used as a direct dynamin inhibitor27 and RNAi directed at 
the clathrin heavy chain (CHC) was used to interfere with clathrin 
function. The functional efficacy of both treatments was shown by 
the reduced labelled transferrin uptake in the cells, a well-charac-
terized  cargo  for  dynamin-  and  clathrin-dependent  endocytosis 
(Fig. 5b). Immunoblotting showed that RNAi treatment effectively 
reduced  overall  CHC  levels  (Fig.  5c).  However,  the  transfection 
efficiency of the RNAi delivery varied in our cell population, with 
some cells showing an almost complete block in transferrin uptake 
and other cells maintaining residual endocytic capacity (Fig. 5b). 
Dynasore and RNAi directed at the CHC did not significantly affect 
RML prion infection or PrPSc internalization (Fig. 5b,d), and no cor-
relation was observed between an individual cell’s susceptibility to 
prion infection and its ability to endocytose transferrin. Macropi-
nocytosis was targeted using the ion transport inhibitor (N-ethyl-
N-isopropyl)amiloride (EIPA)28. This treatment had no effect on 
labelled transferrin uptake and did not affect RML prion infection 
in our system (Fig. 5b,d). Incubating pre-cooled PrP-224AlaMYC 
cells with RML prions at 4 °C confirms that blocking all endocy-
tosis—demonstrated by the lack of transferrin uptake—does not 
ablate prion conversion (Fig. 5b,d).
An  important  role  for  plasma  membrane  PrPC  expression  in 
prion conversion was confirmed by experiments using phosphoi-
nositide-specific phospholipase C (PIPLC) to deplete plasma mem-
brane PrPC. This significantly reduced the generation of MYC-tagged 
PrPSc (Fig. 6a,b). It is interesting to note that many of the cells in the 
PrP-224AlaMYC cultures bind and/or internalize inocula-derived 
PrPSc following RML prion exposure, independent of surface PrPC 
expression (Fig. 6a). Further, striking examples of this phenomenon 
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Figure 3 | MYC-tagged PrPSc is synthesized rapidly, following RML prion 
exposure. (a) PrP-224AlamYC cells were exposed to RmL prions for 72 h, 
then fixed immediately or washed and cultured in fresh media (without 
RmL prions) for the indicated durations before fixation and formic acid 
extraction. The proportion of anti-mYC-positive (RmL prion infected) 
cells fixed at the indicated durations was quantified (red). As a control, 
PrP-KD cells were exposed to RmL prions and processed in parallel (blue). 
The mean ± s.e.m. from four independent experiments are shown. (b) PrP-
224AlamYC cells were exposed to RmL prions for 0–72 h, then fixed and 
extracted with formic acid. The proportion of anti-mYC-positive (RmL 
prion infected) cells fixed at the indicated durations was quantified. The 
mean ± s.e.m. from four independent experiments are shown. Before RmL 
prion exposure (0 h), few PrP-positive cells are detected, whereas RmL 
prion exposure causes the rapid build-up of formic acid-resistant PrP 
(PrPsc) detectable as early as 2 h or less. (c) PrP-224AlamYC cells were 
exposed to RmL prions for 0–32 min, then fixed and extracted with formic 
acid. The proportion of anti-mYC-positive (prion infected) cells fixed 
at the indicated durations was quantified. The mean ± s.e.m. from four 
independent experiments are shown; at the 0-, 1- and 2-min time points, 
the mean ± s.e.m. from eight experiments is shown (*P < 0.05, **P < 0.001, 
two-tailed t-test). (d) PrP-224AlamYC cells were exposed to RmL prions 
for 2 min, then fixed and digested with PK. A confocal image stained 
with anti-mYC antibodies (green) and counterstained with 6-diamidino-
2-phenylindole (blue) is shown. PK-resistant PrP (that is, PrPsc) was 
generated after just 2 min of RmL prion exposure; scale bar, 20 µm.ARTICLE     
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are included in Supplementary Figure S7. This suggests that other 
factors in addition to a simple physical association of cellular PrPC 
with PrPSc affect prion conversion, an observation in agreement 
with previously published data29–31.
Rapid prion conversion on the cell surface may point to a mecha-
nism in which PrP misfolding is a stochastic event catalysed by the 
interaction with PrPSc in a favourable environment such as that found 
in lipid rafts, membrane microdomains thought to have a role in prion 
conversion32. We therefore tested whether reagents that disrupt lipid 
raft integrity would affect prion protein conversion. Two reagents that 
affect lipid raft function by different mechanisms—filipin33, which 
binds and sequesters plasma membrane cholesterol, and U18666A, 
which inhibits cholesterol transport to rafts34—abrogated prion con-
version in our cellular system (Fig. 6c).
Discussion
We report on the generation of a unique cell system in which an 
epitope-tagged  PrPC  is  expressed  in  a  prion-susceptible  neuro-
blastoma cell line in which the host PrPC has been removed using 
RNAi. This engineered PrPC was shown to support prion replication 
resulting in the production of a true bona fide, infectious epitope-
tagged PrPSc. Using this cellular system we have shown that prion 
infection  of  cells  is  extremely  rapid,  occurring  within  1 min  of   
prion  exposure,  and  we  demonstrate  unequivocally  that  the   
plasma membrane is the initial site of prion conversion.
Generating an epitope-tagged PrPC chimera that is capable of 
prion  conversion  and  forming  an  infectious  tagged  PrPSc  is  not 
straightforward.  A  C-terminal  green  fluorescent  protein-tagged 
PrPC construct produced by Barmada and Harris14 failed to form 
PrPSc  and  even  the  insertion  of  a  small  10-amino-acid  MYC 
tag  at  ser-230  of  murine  PrP  abrogated  prion  conversion  when 
expressed in a PrPC knockout mouse background15. We designed 
a panel of eight different constructs based on a biophysical analy-
sis of PrPC structure, and screened them for the ability to recon-
stitute prion propagation in our PrP-KD cells. In agreement with 
an earlier report17 PrP constructs with FLAG tags inserted near the   
N-terminus supported efficient prion conversion, but could not be 
used because this region of the protein was cleaved during the cellu-
lar processing of PrPSc. Epitope tags inserted into the central region 
of the PrPC molecule did not support prion propagation, consist-
ent with previous reports on the importance of sequence conserva-
tion in this region for efficient conversion12,13. However, one of our 
constructs,  PrP-224AlaMYC,  robustly  generated  epitope-tagged 
PrPSc. Significantly, a mouse bioassay demonstrated that the PrP-
224AlaMYC cells propagate genuine infectious prions. The capacity 
of PrP-224AlaMYC cells to produce epitope-tagged PrPSc, combined 
with effective protocols to remove PrPC from our cells, allowed us 
to examine PrP misfolding when prions initially contact and infect 
susceptible cells.
Our temporal analysis of the events immediately following cellu-
lar prion exposure revealed that prion infection is far faster than   
previously  thought.  Earlier  studies  had  indicated  that  PrPSc/cell 
interactions may be rapid35, but de novo PrPSc formation was not 
studied directly. Here we have demonstrated in a cellular system 
the rapid protein misfolding and aggregation observed in cell-free 
experiments36. Consistent with the highly dynamic nature of prion 
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Figure 4 | Prion conversion first occurs at the cell surface within 1 min of 
prion exposure. (a) PrP224-AlamYC cells were exposed to RmL prions 
for the indicated durations, and then fixed and extracted with formic acid 
before staining with anti-mYC antibodies (green) and counterstaining 
with 6-diamidino-2-phenylindole (DAPI, blue). orthogonal projections 
(red and green squares) of serial confocal sections are shown alongside 
one z-section taken from the middle of the cell (as indicated by the 
guidelines). A cell fixed after a 1-min exposure to RmL prions shows PrPsc 
immunostaining only at the cell surface (1 min, white arrow). An adjacent 
cell in the field that has high levels of plasma membrane PrPsc also shows 
low intracellular levels of PrPsc (1 min, yellow arrow). Cells exposed to 
RmL prions for 180 min show the typical steady-state distribution of PrPsc, 
with strong immunostaining at the plasma membrane (white arrows) 
and in the perinuclear region (yellow arrow  − 180 min); scale bar, 10 µm. 
(b) Quantification of cell phenotypes observed at different time points 
following prion exposure (the mean ± s.e.m. from four independent 
experiments are shown; *P < 0.05, **P < 0.01, two-tailed t-test. The exact 
P-values are: membrane 1–2 min, 0.022; membrane 1–4 min, 0.049; 
membrane/PnC 1–2 min, 0.0049; membrane PnC 1–4 min, 0.0057).  
(c) PrP-224AlamYC cells were exposed to RmL prions and Texas red-
labelled transferrin (red) for the indicated durations, then fixed and 
extracted with formic acid. merged confocal images of cells stained 
with anti-mYC antibodies (green) and counterstained with DAPI (blue) 
are shown; scale bar, 20 µm. Initially, PrPsc shows a plasma membrane 
distribution (1 min, arrows) and/or diffuse intracellular distribution (2 min, 
arrows) and then rapidly attains its steady-state distribution concentrated 
at the plasma membrane and PnC (4 min, white arrow indicates strong 
PnC stain). Initially, transferrin could be observed in small puncta at the 
cell periphery, reaching its equilibrium distribution in recycling endosomes 
at the PnC (yellow arrows) between 8 and 16 min.ARTICLE
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infection  of  PrP-224AlaMYC  cells,  we  observed  that  PrPSc  had 
attained steady-state levels by 2 h following RML prion exposure and 
did not change significantly up to 24 h, indicating that PrPSc metab-
olism is highly dynamic and the synthesis and breakdown appear 
normally balanced in these cells. A detailed spatial analysis of cells 
shortly after prion exposure demonstrated that PrPSc forms on the 
plasma membrane. The plasma membrane has been suggested to be 
a potential site of PrP conversion7,21,22,37, which is consistent with the 
observed PrPSc distribution reported in different cell and in vivo sys-
tems21,24,38. Our observations that prion conversion proceeds even 
at 4 °C under conditions that prohibit endocytic activity in mam-
malian cells26 confirms that the plasma membrane alone is sufficient   
for the process. Supporting this idea, we have also shown that plasma 
membrane PrPC expression is required for efficient prion infection. 
PIPLC treatment effectively removed plasma membrane PrPC from 
PrP-224AlaMYC cells and greatly reduced the generation of PrPSc. 
This is consistent with previous reports showing that PIPLC treat-
ment reduced the generation of PrPSc in chronically prion-infected 
PK1 cells39, and data indicating that PrPC lacking the GPI anchor 
(and hence not expressed on the cell surface) does not support   
efficient PrPSc production or stable cellular prion infection40.
The  role  of  the  plasma  membrane  in  prion  conversion  was   
explored further by experimental treatments designed to inhibit 
dynamin/clathrin-dependent  endocytosis  and  macropinocytosis, 
pathways that have been previously implicated in prion metabo-
lism35,41. These manipulations had little effect on prion infection or 
PrPSc internalization. This suggests that either they are not involved 
in PrPSc internalization or that the process can occur through mul-
tiple pathways, an idea supported by the literature32. Our data also 
suggest  that  prion  conversion  is  dependent  on  the  presence  of   
intact lipid rafts, specialized membrane microdomains known to be 
present in the plasma membrane and enriched in PrPC (refs 42,43). 
Supporting this idea, cofactors enriched in lipid rafts have been 
shown to stimulate synthetic prion conversion29,31 and reagents that 
disrupt raft integrity abrogate PrPSc propagation in cells44,45. Despite 
this, our data do not preclude a role for intracellular compartments 
in prion conversion, which may continue or accelerate the process 
following the endocytosis of PrPSc. Previous reports have impli-
cated various cell compartments in the conversion process7,46,47. Our 
observation that prion infection was reduced at 4 °C may reflect 
a slower reaction rate due to the lower temperature as might be 
expected for a protein-folding-driven phenomenon, but could also 
be consistent with an important role for internal compartments in 
PrPSc propagation. As earlier studies relied on the analysis of cells 
already propagating prions that express intracellular PrPSc before 
any manipulations designed to examine the region at which mis-
folding takes place7,47,48, the contribution of the plasma membrane to 
the initial prion conversion process may have been underestimated 
or overlooked.
Our system has also allowed new insights into the dynamic nature 
of PrPSc trafficking in the cell. The ability to analyse the trafficking 
events immediately following prion exposure has revealed that PrPSc 
initially forms at the cell surface, and is rapidly endocytosed. Indeed, 
after 1 min of exposure to RML prions, many cells already contain 
intracellular PrPSc, often in a diffuse cellular distribution, possibly 
reflecting a transition through an endosomal compartment. After 
4 min of exposure to prions, PrPSc takes up a steady-state distribu-
tion concentrated at the PNC and at the cell surface, as described in 
the literature20,22,23. The similarity in the appearance of these cells to 
cells that chronically propagate prions, and our data showing that a 
2-min exposure to RML prion brain homogenate is sufficient to gene-
rate cells that continue to produce PrPSc in the absence of further 
prion seed, suggests that cells are stably infected by prions in a very 
short time period. However, membrane binding and internalization 
of inocula-derived PrPSc is not in itself sufficient to generate prion 
infection/de novo PrPSc production. This is clearly demonstrated by 
our novel cell system and suggests that cell factors, in addition to a 
simple physical interaction between PrPC and PrPSc, are required for 
prion formation. This idea has been postulated previously29,31 and is 
supported by our demonstration that increasing the concentration 
of inocula added to our PrP224AlaMYC cultures did not lead to an 
increase in the proportion of infected cells. This indicates that only a 
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Figure 5 | PrPSc forms at the cell surface. (a) Pre-cooled PrP-224AlamYC 
cells were exposed to RmL prions for 2 min on ice, then fixed and extracted 
with formic acid. orthogonal reconstructions of serial confocal slices 
are shown (red and green boxes) alongside one z-slice taken from near 
the middle of the cells (as indicated by the guide lines). The cells were 
fixed after 2 min and stained with anti-mYC antibodies (green) and 
counterstained with 6-diamidino-2-phenylindole (DAPI, blue); scale bar, 
20 µm. Formic acid-resistant PrP (PrPsc) is formed on the cell surface of one 
of the cells in the field (arrow), no intracellular PrPsc was detected. (b) PrP-
224AlamYC cells were mock-transfected or transfected with RnAi directed 
at CHC, pretreated with dynasore (80 µm), EIPA (100 µm) or pre-cooled to 
4 °C. RmL prions were added in the continued presence of the treatments 
for 180 min and Texas red-labelled transferrin (red) was added for the final 
10 min of incubation. The cells were then fixed and extracted with formic 
acid. merged confocal images of cells stained with anti-mYC antibodies 
(green) and counterstained with DAPI (blue) are shown; scale bar, 20 µm. 
Following prion exposure at 4 °C, mYC-tagged PrPsc was detected only 
at the plasma membrane (arrow). (c) Lysates from PrP-224AlamYC cells 
mock-transfected or transfected with RnAi directed at CHC were collected 
and subjected to sDs–polyacrylamide gel electrophoresis. Immunoblots 
developed with anti-CHC and anti-actin antibodies are shown. Quantitative 
densitometry of similar blots showed that CHC expression was reduced 
by ~70% in the RnAi-treated cells. (d) PrP-224AlamYC cells were treated 
as in b. The percentage of anti-mYC-positive (RmL prion infected) cells 
observed was quantified for each condition. The mean ± s.e.m. from 
three independent experiments are shown (background levels found in 
uninfected cells for each condition have been subtracted from the mean).ARTICLE     
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proportion of our cells contain/express the necessary susceptibility 
factors required for prion conversion.
In conclusion, we have presented the generation of a unique cell 
system producing bona fide epitope-tagged PrPSc, which was ana-
lysed using both in vitro and in vivo assays. By visualizing MYC-
tagged PrPSc, we have been able to study the earliest events in cellu-
lar prion conversion. We have shown that cellular prion infection is 
a dynamic process that occurs within 1 min of prion exposure, and 
that the plasma membrane is the primary site of prion conversion. 
These results have important implications for our understanding of 
the conversion and spread of prions in vivo. Once a sufficient seed of 
infectious prions has been established in the brain, our data suggest 
that prion cellular spread is likely to proceed far more rapidly than 
previously thought. These data cast new light on why prion infec-
tion can be very aggressive in vivo and can affect the whole neural 
axis in just a few weeks.
Methods
Cell lines and DNA constructs. All cells were cultured in OptiMEM, FCS 
(10%) and penicllin/streptomycin. Short interfering RNA sequences targeting 
the 3′-UTR of PrPC were cloned into the pSUPER.retro.puro expression vector 
(Oligoengine) and introduced into wild-type PK1 cells by retroviral transduc-
tion49. Stable PrP knockout clones (Supplementary Fig. S1) were isolated and 
cultured in puromycin selection media. Tagged PrP constructs were gener-
ated by overlap extension PCR procedures using standard methods50 (primer 
sequences available on request), subcloned into the pLNCX-retroviral vector 
and then sequenced (Clontech). These were introduced into PK1-KD cells by 
retroviral transduction51, and stable lines expressing the tagged PrP constructs 
were isolated and routinely cultured in dual selection media (puromycin and 
G418, Invitrogen).
Cellular prion infection and PrPSc analyses. Brain homogenates were prepared 
from end-stage RML prion-infected CD-1 mice as a 10% homogenate in PBS16. 
These were diluted to 0.1% in media, and added to cells grown to 70% confluence 
that were seeded on poly-l-lysine-coated glass coverslips or plastic dishes. After 
prion incubation, cells were washed three times with warm PBS and fixed,  
collected for biochemical analysis or passaged in the ratio 1:8. The Scrapie Cell 
Assay was performed as described previously16. Cells were routinely prepared for 
immunofluorescence analysis by fixation in 3.7% paraformaldehyde for 12 min  
at 37 °C, and then washing in PBS. PrPSc was revealed specifically by a 5-min  
pre-treatment with 98% formic acid to remove host PrPC (ref. 20). PK digestion 
and GdnHCl treatment to remove PrPC and expose PrPSc were as described21.
To further characterize prion infection, PrP-224AlaMYC cells were exposed 
to varying concentrations of RML prions for 180 min before fixation, or incubated 
with 0.1% RML prions for 2 min, washed three times and fixed immediately or 
incubated in fresh medium lacking prions for a further 48 h before fixation. In 
addition, cells were pretreated with vehicle, dynasore (80 µM—added in serum-free 
media), EIPA (100 µM) and filipin (5 µg ml − 1) for 30 min, or U18666A (1 µg ml − 1) 
for 16 h, and then exposed to RML prions. Cells were transfected with RNAi oligos 
using Fugene 6 reagent according to the manufacturer’s instructions. A mixture 
of four RNAi oligos targeting CHC (Dharmacon on target plus kit) was added at 
100 nM for 30 h before the addition of RML prions. PIPLC treatment was carried 
out using 0.5 U ml − 1 PIPLC for 2 h before the addition of RML prions39. The cells 
were then incubated with RML prions for 180 min in the continued presence of 
the treatment. Texas red-labelled transferrin (Invitrogen) was added to the media 
at 5 µg ml − 1 for the last 10 min of the incubation. Control experiments replicating 
the conditions for each treatment but lacking the active reagents were carried out 
to check that conditions outside our treatments did not affect prion infection. No 
significant differences were observed. In our 4 °C experiments (Fig. 5a,b), cells 
were pre-cooled on ice for 30 min before the addition of RML prions made up in 
ice-cold media. Cells were washed three times with ice-cold PBS, fixed on ice for 
10 min and then transferred to 37 °C for a further 10 min before washing with PBS 
and further processing.
Immunofluorescence analysis. Formic acid-treated and -untreated cells were 
permeabilized with cold methanol for 10 min at  − 20 °C and then washed with 
PBS, before blocking with 10% horse serum and 1% BSA in TBS. Primary antibody 
incubations were performed overnight at 4 °C in TBS/1% BSA. Following extensive 
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Figure 6 | Plasma membrane PrPC is required for efficient prion 
infection. (a) upper panel: PrP-224AlamYC cells were treated with PIPLC 
(0.5 u ml − 1) for 2 h before fixation and immunostaining with anti-PrP 
antibodies (red) and counter staining with 6-diamidino-2-phenylindole 
(DAPI, blue). merged confocal images are shown; scale bar, 20 µm. 
Control cells ( − PIPLC) show strong plasma membrane (white arrow) and 
intracellular (yellow arrow) PrP immunostaining. PIPLC effectively removed 
surface plasma membrane-bound PrP ( + PIPLC), but residual intracellular 
PrP immunostaining was seen (yellow arrow). Lower panel: untreated 
and PIPLC-treated PrP224AlamYC cells were exposed to RmL prions 
for 180 min, then fixed and extracted with formic acid. merged confocal 
images of cells stained with anti-mYC (green) and anti-PrP antibodies 
(red), then counterstained with DAPI (blue) are shown; scale bar, 20 µm. 
Formic acid-resistant PrPsc derived from the inocula and immunostained 
with anti-PrP antibodies only (red) can be seen closely associated with all 
the cells independent of PIPLC treatment (examples are indicated by white 
arrows). one untreated cell ( − PIPLC, yellow arrow) in the field shown has 
generated de novo mYC-tagged PrPsc as indicated by anti-mYC (green) and 
anti-PrP (red) immunostaining, which appears yellow in the merged image. 
no cells have generated mYC-tagged PrPsc following PIPLC treatment 
( + PIPLC). (b) PrP-224AlamYC cells were treated as in Figure 6a lower 
panel. The percentage of anti-mYC-positive (RmL prion infected) cells was 
quantified for each condition. The mean ± s.e.m. from three independent 
experiments are shown (background levels found in uninfected cells for 
each condition have been subtracted from the mean). (c) PrP-224AlamYC 
cells were pretreated with vehicle (Dmso) or filipin (5 µg ml − 1) for 
30 min, or u18666A (1 µg ml − 1) for 16 h, then exposed to RmL prions for 
180 min in the continued presence of the vehicle or inhibitor. Cells were 
then fixed and extracted with formic acid before immunostaining with 
anti-mYC antibodies. The percentage of anti-mYC-positive (RmL prion-
infected) cells was quantified. The mean ± s.e.m. from three independent 
experiments are shown (background levels found in uninfected cells for 
each condition for have been subtracted from the mean).ARTICLE
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washing in TBS, samples were incubated with AlexaFluor 488 and 543-labelled 
secondary antibodies diluted in TBS/1% BSA, as appropriate, for 1 h at room 
temperature. Cells were thoroughly washed in TBS and mounted in Antifade 
media (DAKO) containing 1-µg ml − 1 4′,6-diamidino-2-phenylindole. The primary 
antibodies used in this study are detailed in Supplementary Table S1. Fluorescence 
images were acquired using a Zeiss LSM510 meta confocal microscope (Zeiss) 
with a plan-Apochromat’ ×63/1.40 oil DIC objective. Control uninfected cells 
were processed for each experiment and LSM settings were chosen to produce 
minimal background staining. The same settings were used to examine all infected 
cells in that experiment. The extent of MYC label incorporated into the cells was 
determined using Volocity software (Improvision). At least 50 cells from three 
independent experiments were analysed per condition. Orthogonal projections 
were generated from z-stacks using Zeiss LSM software (Zeiss). To determine prion 
infection, at least 300 cells from eight randomly chosen fields were counted for 
each condition, and the proportion of cells showing PrPSc immunostaining after 
PrPC removal was calculated. All experiments were performed by two independent 
investigators. Blinded analysis by a third investigator was also undertaken. For cell 
phenotypic analyses, z-stacks encompassing the entire cell were obtained and cells 
were grouped into one of three categories based on the localization of MYC-tagged 
PrPSc: exclusively plasma membrane, plasma membrane/diffuse intracellular and 
plasma membrane/PNC. In each experiment, at least 50 cells were analysed for 
each condition.
Inoculation of tg20 mice and neuropathological analysis. Inocula were 
prepared from PK1, PrP-KD and PrP-224AlaMYC cell cultures exposed to prions 
for 72 h and sub-passaged five times 1:8 (ref. 16). Cells were harvested in sterile 
PBS, washed twice and then resuspended to 30 million cells per ml. Control PrP-
224AlaMYC cells that were not exposed to prions were collected the same way.  
Inocula were stored in sterile vessels at  − 80 °C until use. Animals were cared for 
per institutional and Home Office regulations. For each of the test conditions, 
groups of five tg20 mice were inoculated intracerebrally with 30 µl of cell suspen-
sion. Animals were observed daily for clinical signs and culled on diagnosis of 
prion disease. Two animals that were not diagnosed with prion disease were culled 
in parallel with the diseased animals, and the remaining animals were culled  
4 to 5 weeks after the last diseased animal was diagnosed. Brains were excised  
and examined by histopathology and western blotting52.
Biochemical analysis. Cell lysates were collected for biochemical analysis in PBS, 
washed and resuspended in a small volume of fresh PBS52,53. The cells were lysed by 
three freeze/thaw cycles and benzonase (50 U ml − 1, Merck) was added for 20 min at 
4 °C. Protein concentrations in the lysates were determined by Bio-Rad assay (Bio-
Rad). For PK treatments, the samples were diluted to 2 mg ml − 1 in PBS and Triton 
X-100 (1%) and PK (5 or 2.5 µg ml − 1) was added. Samples were digested for 30 min 
at 37 °C and digestion was terminated by the addition of phenylmethylsulphonyl 
fluoride to a 1-mM sample. Proteins were precipitated with cold methanol and 
resuspended in SDS sample buffer. SDS–polyacrylamide gel electrophoresis and 
immunoblotting were carried out as described previously52.
Statistical analysis. Data were expressed as mean plus standard error of the mean 
(s.e.m.), unless otherwise stated. Data were compared by two-tailed t-tests and 
considered significantly different when P < 0.05. Degree of significance is expressed 
as follows: P < 0.05*; P < 0.01**; unless otherwise specified. 
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